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Abstract
Treatment‐free remission (TFR) by tyrosine kinase inhibitors (TKI) discontinuation 
in patients with deep molecular response (DMR) is a paramount goal in the current 
chronic myeloid leukemia (CML) therapeutic strategy. The best DMR level by real‐
time quantitative PCR (RT‐qPCR) for TKI discontinuation is still a matter of debate. 
To compare the accuracy of digital PCR (dPCR) and RT‐qPCR for BCR‐ABL1 tran-
script levels detection, 142 CML patients were monitored for a median time of 
24 months. Digital PCR detected BCR‐ABL1 transcripts in the RT‐qPCR undetecta-
ble cases. The dPCR analysis of the samples, grouped by the MR classes, revealed a 
significant difference between MR4.0 and MR4.5 (P = 0.0104) or MR5.0 (P = 0.0032). 
The clinical and hematological characteristics of the patients grouped according to 
DMR classes (MR4.0 vs MR4.5‐5.0) were superimposable. Conversely, patients with 
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1 |  INTRODUCTION
Therapy with tyrosine kinase inhibitors (TKI) changed the 
fate of chronic myeloid leukemia (CML). Two decades after 
the introduction of imatinib (IM), the life expectancy of CML 
patients treated with TKI has approached to that of the gen-
eral population1 and, now, the new objectives are focused on 
improving the management of the disease and, possibly, the 
quality of life of the patients.2-4
The current policy of CML therapy with TKI is to achieve 
a faster major molecular response (MMR or MR3.0 = BCR‐
ABL1/ABL1 IS ≤0.1%) to prevent the progression to blastic 
phase and to obtain a deep molecular response (DMR or MR4.0 
if ≤0.01% BCR‐ABL1/ABL1 %IS, or MR4.5 if ≤0.0032% 
BCR‐ABL1/ABL1 %IS or MR5.0 if ≤0.001 BCR‐ABL1/ABL1 
%IS) to gain the opportunity of a treatment discontinuation.5
The results from the Stop IMatinib (STIM) and TWISTER 
pivotal trials challenged the rule that TKI therapy should be 
continued lifelong. Since then, both IM6-8 and second‐gen-
eration TKI discontinuation studies9,10 confirmed that about 
50‐60% of patients with a DMR can successfully stop TKI, 
achieving a treatment‐free remission (TFR). These important 
clinical trials demonstrated that TKI discontinuation did not 
cause CML‐related deaths and, moreover, molecular relapses 
are still sensitive to therapy resumption.11,12
As mentioned above, TFR is one of the most important 
objectives in CML patients, and recently, TKI discontinu-
ation has become a reality also in clinical practice. In fact, 
in June 2017, the European Society of Medical Oncology 
(ESMO) introduced the option of TKI interruption out of 
the clinical trials too.13 However, patients’ inclusion criteria 
for discontinuation such as the prognostic score, the overall 
duration of TKI treatment, the “stable” DMR and the levels 
of DMR are still matters of debate. Therefore, the TKI dis-
continuation strategy cannot be considered as optimized in 
this setting. Clinically relevant questions were addressed also 
by the French CML Study Group, which recently published 
the recommendations on discontinuation of TKI in CML for 
clinical practice.12 They remark the importance of determin-
ing the best level of DMR for TKI discontinuation. Clinical 
evidences unexpectedly highlight the absence of a linear cor-
relation between the depth of the DMR, quantified follow-
ing the IS, and the TFR maintenance rate. One of the causes 
could be related to the intrinsic limitations of real‐time quan-
titative PCR (RT‐qPCR), particularly concerning its lack of 
precision, especially in the quantification of the low levels of 
the target, and the variation of its sensitivity from one test to 
another.14,15
For these reasons, the great majority of patients who 
undergo TKI discontinuation frequently have a DMR with 
undetectable levels of BCR‐ABL1 transcript by RT‐qPCR, 
Overall, according to the published data, 50%‐60% of pa-
tients with undetectable DMR by RT‐qPCR are expected to 
lose the DMR.16-19
Therefore, the RT‐qPCR cannot be considered as an op-
timal tool neither to select the best candidates for treatment 
discontinuation nor to design personalized treatment pro-
grams, especially in the era of the more potent second‐gen-
eration TKI.
In the last years, the digital PCR (dPCR) has emerged as a 
more sensitive and accurate detection tool of minimal resid-
ual disease (MRD) and this increased the interest for its use 
in the clinical practice.20-22 The dPCR provides an absolute 
target sequence quantity, and recently, the alignment of the 
dPCR values <0.468 BCR‐ABL1 copies/µL (as we previously described) showed a 
longer DMR duration (P = 0.0220) and mainly belonged to MR4.5‐5.0 (P = 0.0442) 
classes compared to patients with higher dPCR values. Among the 142 patients, 111 
(78%) discontinued the TKI treatment; among the 111 patients, 24 (22%) lost the 
MR3.0 or MR4.0. RT‐qPCR was not able to discriminate patients with higher risk of 
MR loss after discontinuation (P = 0.8100). On the contrary, according to dPCR, 
12/25 (48%) patients with BCR‐ABL1 values ≥0.468 and 12/86 (14%) patients with 
BCR‐ABL1 values <0.468 lost DMR in this cohort, respectively (P = 0.0003). 
Treatment‐free remission of patients who discontinued TKI with a dPCR <0.468 was 
significantly higher compared to patients with dPCR ≥ 0.468 (TFR at 2 years 83% vs 
52% P = 0.0017, respectively). In conclusion, dPCR resulted in an improved recogni-
tion of stable DMR and of candidates to TKI discontinuation.
K E Y W O R D S
chronic myeloid leukemia, digital PCR (dPCR), minimal residual disease (MRD) monitoring, treatment‐
free remission (TFR), tyrosine kinase inhibitors (TKI) discontinuation
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methods for BCR‐ABL1 transcript quantification by using 
the Qx100/Qx200 Droplet Digital PCR System (Biorad) and 
the QuantStudio 3D Digital PCR System (Thermofisher) has 
been accomplished.23
Although the dPCR is not yet routinely applied for the 
standard analysis of molecular MRD in CML, preliminary 
data suggest that it is more sensitive and accurate than RT‐
qPCR for monitoring the BCR‐ABL1 transcript levels and, 
possibly, for predicting the patients who are going to relapse 
after discontinuation of TKI.24
This study focused on the MRD RT‐qPCR/dPCR compar-
ative monitoring in 142 CML patients treated with TKI and 
with durable DMR (>2 years), as conventionally assessed by 
RT‐qPCR, before the enrollment.
The aim of this study was to evaluate the reliability and 
the efficiency of dPCR for a better evaluation of “stable” 
DMR and for a better selection of the candidates for treat-
ment discontinuation.
2 |  METHODS
2.1 | Patients
In total, 142 CML patients treated with TKIs (IM, nilotinib 
[NIL], or dasatinib [DAS]) for a median of 99 months (range 
14‐215) and with durable (≥2 years) RT‐qPCR DMR (me-
dian 71 months; range 24‐171) were enrolled into the study, 
approved by the Ethical Committee of each participating 
Center. The patients were recruited by 10 Italian Hematologic 
Centers belonging to the CML GIMEMA (Gruppo Italiano 
Malattie Ematologiche dell'Adulto) Working Party. The clin-
ical and hematological features of the patients, at the time of 
the enrollment, included: age, type of BCR‐ABL1 transcript, 
Sokal risk distribution at diagnosis, the first‐ and second‐line 
TKI treatment, treatment dosage and duration, time to com-
plete cytogenetic response (CCyR), MMR, DMR, and best 
molecular response (MR).
Table 1 reports the cohort's characteristics according to 
DMR class at the time of the enrollment into the study. Of 
the 142 cases, 116 (82%) had more than 24 months of DMR 
when they were enrolled and started (Time point 0) to be 
comparatively evaluated by the conventional RT‐qPCR and 
dPCR (RT‐qPCR/dPCR).
The patients were grouped into two pairs of DMR classes: 
the ones with MR4.0 vs the MR4.5‐5.0, and the ones with ≥0.468 
vs those with <0.468 BCR‐ABL1 copies/µL, according to the 
dPCR cutoff value of 0.468 BCR‐ABL1 copies/µL, discrim-
inating the deep molecular responders, as previously re-
ported.24 A new receiver operating characteristic (ROC) curve 
analysis was carried out on the present cohort of patients and 
confirmed the reliability of the abovementioned cutoff in 
identification of the DMR patients by dPCR. (Figure S1).24
The assignment of DMR class, by using the RT‐qPCR val-
ues, was based on the results of the first RT‐qPCR evaluation, 
at the time of enrollment (Time point 0). In particular, at the 
Time point 0, according to RT‐qPCR results, 60 (42%) out 
of 142 patients had an MR4.0, and 32 (53%) out of 60 cases 
had MR4.0 undetectable; 82 (58%) had an MR4.5 or MR5.0 
and 54 (66%) out of 82 cases were undetectable. On the other 
hand, according to dPCR results, 31 (22%) out of 142 patients 
had ≥0.468 BCR‐ABL1 copies/µL, and 111 cases (78%) had 
<0.468 BCR‐ABL1 copies/µL. (Table 1).
The median time of concomitant RT‐qPCR/dPCR moni-
toring was 24 months (range 12‐40). The median follow‐up 
of the entire cohort is 19 (1‐76).
Of note, 111 (78%) out of 142 patients discontinued the 
TKIs therapy. Fifty (45%) of patients who discontinued 
TKI therapy were enrolled in different discontinuing trails: 
ENESTFreedom (5/111, 4.5%), ENESTpath (8/111, 7.2%), 
and NP0 in Brescia (37/111, 33.3%).
Sixty‐one patients (55%) discontinued TKIs therapy out 
of clinical trials according to the Center policy based on clin-
ical practice and shared patient's decision. All patients were 
evaluated at the time of discontinuation and after the discon-
tinuation, while 13 cases were monitored also before the dis-
continuation of treatment (Table 2).
During the monitoring period, a total of 556 peripheral 
blood samples were comparatively analyzed by RT‐qPCR/
dPCR.17,24,25
The study was performed according to good clinical prac-
tice and Helsinki's Declaration, and the patients gave their 
informed consent.
2.2 | RT‐qPCR and dPCR analyses
Conventional RT‐qPCR measurements were carried out at 
the Reference Laboratory of each participating Center, ac-
cording to ELN Guidelines.4,25-27 At each time point sched-
uled for the MRD monitoring, 10 mL of peripheral blood was 
sampled and used for RT‐qPCR analysis.17,24
Molecular responses by RT‐qPCR were defined accord-
ing to the latest laboratory recommendations and using ABL1 
as a housekeeping gene.24 Measurable MR was assigned 
following the international scale (IS) and scored MR4.0 if 
≤0.01% BCR‐ABL1 %IS, MR4.5 if ≤0.0032% BCR‐ABL1 
%IS, and MR5.0 if ≤0.001 BCR‐ABL1 %IS. Minimum sum 
of ABL1 reference gene transcripts, irrespective of whether 
BCR‐ABL1 was detected or not, 10.000, 32.000, and 100.000 
for MR4.0, MR4.5, and MR5.0, respectively.24
The participating reference laboratories belonged the 
Gimema Labnet and accredited by the Gimema Labnet 
Quality Committee to release the results of RT‐qPCR anal-
ysis, since certified for the quantification of BCR‐ABL1 
according to the IS, as recommended by the International 
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Experts Panel's Guide Lines.25 These analysis were per-
formed as detailed in Data S2.
To the purpose of our study, the loss of the MR was defined 
as loss of MR3.0 according to ENESTFreedom and ENESTpath 
criteria (13 cases) or as “at least two positive RT‐PCR results 
showing a significant increase (by 10 times; ie, one log), at 
two consecutive assessments or loss of major molecular re-
sponse (MMR)” according to what reported by STIM study 
(98 cases).6The dPCR analysis was performed on the same 
cDNA samples used for RT‐qPCR, in order to limit the retro-
transcription step variability.28 Therefore, each patient enrolled 
in the study was comparatively analyzed for the BCR‐ABL1 
transcript by RT‐qPCR and by dPCR at every time point.
The dPCR analysis was centralized at the Laboratory 
CREA (Centro di Ricerca Emato‐Oncologico AIL) of the 
ASST Spedali Civili of Brescia and performed as previously 
described.24
Briefly, the cDNA was quantified using a Quant‐
iT™ OliGreen® ssDNA kit (Thermofisher Scientific) by 
Infinite200 (Tecan) and diluted at 50 ng/µL since this quan-
tity resulted the best to obtain a deep quantification and to 
avoid the saturation of the chip.
We prepared 16 μL of reaction mix containing 8 μL of 
2X QuantStudio 3D Digital PCR Master Mix (Thermofisher 
Scientific), 0.8 μL of 20X TaqMan‐MGB‐FAM‐probe assay, 
1.1 μL of diluted cDNA, and 6.1 μL of nuclease‐free water 
(Qiagen). The negative control reaction mix contained 8 µL 
of 2X QuantStudio 3D Digital PCR Master Mix, 0.8 μL of 
20X TaqMan‐MGB‐FAM‐probe assay, and of 7.2 μL nucle-
ase‐free water. One negative control was loaded every ther-
mal cycling run containing samples prepared with the same 
mix. The reverse transcription negative control reaction mix 
contained 8 μL of 2X QuantStudio 3D Digital PCR Master 
Mix, 0.8 μL of 20X TaqMan‐MGB‐FAM‐probe assay, 
1.2 μL of reverse transcription blank, and 6.1 μL of nucle-
ase‐free water.
For each sample, we loaded 15 μL of the reaction mixes 
onto a QuantStudio 3D Digital PCR 20K Chip (Thermofisher 
Scientific) using the automatic chip loader and the signal was 
amplified by the following thermocycling profile: 95°C for 
8 minutes, 45 cycles at 95°C for 15 seconds, and 60°C for 
1 minute, with a final extension step at 60°C for 2 minutes. 
The amplification was followed by the chips imaging and 
the secondary analysis performed with the QuantStudio 3D 
AnalysisSuite Cloud Software. All samples were analyzed 
twice by different operators and the final results were ex-
pressed as means of the number of BCR‐ABL1 copies/µL of 
reaction of the replicates.24
2.3 | Statistical analysis
Clinical and laboratory data were categorized as continuous 
or categorical variables. The t test or Mann‐Whitney and 
chi‐square were used to compare the continuous and cat-
egorical variables, respectively. The t test with Welch's cor-
rection has been used in the evaluation of dPCR subgroups 
as unbalanced sample sizes had to be taken into account (in 
fact 111 and 31 patients in the overall cohort, and 86 and 
25 patients in the discontinuation cohort presented dPCR 
lower and higher than 0.468, respectively). Normality dis-
tribution of variables was assessed by a Shapiro‐Wilk test. 
The type of analysis performed is stated in figures’ and ta-
bles’ legends.
Treatment‐free remission was calculated from the date 
of TKI withdrawal to the date of loss of MR3.0 or MR4.0 or 
last control by the Kaplan‐Meier method. Comparison of 
subgroups was carried out by the log‐rank test. Univariate 
Cox regression analysis was used to evaluate the association 
of variables with TFR. Variables included age at diagnosis, 
sex, previous therapy with IFN, time to MMR and DMR, 
Sokal class, type of transcript, time to discontinuation, use 
of frontline second‐ generation TKIs, MR classes consid-
ering detectable and undetectable transcript, and dPCR. 
Multivariable analysis has been performed on dPCR values 
and, by univariate analysis, the duration of DMR resulted 
significant.
Receiver operator curves analysis was done to recalculate 
the optimal dPCR cutoff value to discriminate the patients 
with DMR and lower probability to lose MR3.0 after TKI 
discontinuation. Notably, a cutoff of 0.468 was found to be 
coincidental with the previous one identified discriminating 
the deep molecular responders by dPCR.24 This value divided 
patients with lower risk of disease molecular relapse better, 
with an area under the curve of 0.69 (CI 95% 0.57‐0.81), 
specificity of 85% and sensitivity of 54% (Figure S1). All 
p‐values are two‐sided and significance level has been set 
below 0.05. Statistical analyses were conducted with EZR 
software (version 1.33), as previously described.29
3 |  RESULTS
This study aimed to comparatively evaluate the efficiency 
and the reliability of the RT‐qPCR and dPCR for the rec-
ognition of an accurate and “stable” DMR and selection of 
candidates to TKIs discontinuation.
For that purpose, 142 CML patients with a durable RT‐
qPCR DMR (≥2 years) were comparatively monitored by 
RT‐qPCR/dPCR every 3‐4 months for a median time of 
24 months (range 12‐40), from the time of enrollment (first 
RT‐qPCR/dPCR analysis = Time point 0) thereafter (last fol-
low‐up). Furthermore, 111/142 patients underwent treatment 
discontinuation and were valuable for TFR.
First, the levels of BCR‐ABL1 minimal residual disease, as 
conventionally assessed by RT‐qPCR, were correlated with 
the dPCR values measured at the same time points.
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The 556 samples comparatively analyzed by RT‐qPCR 
and dPCR are plotted in Figure 1. RT‐qPCR BCR‐ABL1 re-
sults were grouped into MR4.0, MR4.5, and MR5.0class (“X 
axis”). When the same samples were analyzed by dPCR, 
different levels of BCR‐ABL1 copies were measured (“Y 
axis”). The numbers of BCR‐ABL1 copies/µL in each MR 
class resulted heterogeneous and widely dispersed, even the 
relative medians and range were progressively decreasing 
moving from the MR4.0 class to MR5.0class. The difference 
was statistically significant between the MR4.0 class and the 
MR4.5 (P = 0.0104) or the MR5.0 class (P = 0.0032), but 
not between the MR4.5 and the MR5.0 classes (P = 0.2021) 
(Figure 1).
Then, we comparatively analyzed the course of RT‐qPCR 
monitoring in the MR4.0 and MR4.5‐5.0 patients, as well as the 
course of molecular dPCR monitoring in the patients with ≥ 
and <0.468 BCR‐ABL1 copies/µL (Figure 2).
The patients grouped into the MR4.0 and MR4.5‐5.0 class 
by RT‐qPCR started from the same MR determined at Time 
point 0 (Figure 2A,B); on the other hand, patients with dPCR 
≥0.468 BCR‐ABL1 copies/µL, at the Time point 0, presented 
different levels of molecular MRD and had a median value 
of 0.758 (range 0.469‐2.806), while patients with dPCR 
<0.468 copies/µL presented lower levels of BCR‐ABL1 
copies and their median value was of 0.171 (range 0‐0.467) 
(Figure 2C,D).
No difference between the monitoring course of MR4.0 
and MR4.5‐5.0 classes could be appreciated and measured. 
Instead, observing the course of dPCR MRD molecular mon-
itoring, the patients belonging the group below the cutoff 
of <0.468 BCR‐ABL1 copies/µL seemed to show lower and 
more “stable” levels of MRD along all the time of monitor-
ing (Figure 2D). During the follow‐up, patients with dPCR 
<0.468 BCR‐ABL1 copies/µL at the Time point 0, presented 
a median value of 0.175 copies/µL (range 0‐1.348), while pa-
tients with dPCR ≥0.468 copies/µL presented higher levels 
of BCR‐ABL1 copies and had a median value of 0.393 copies/
µL (range 0‐2.195). The differences at Time point 0 and the 
variations during the follow‐up period did not result statisti-
cally significant between the two groups.
In order to evaluate the correlation between the DMR, the 
characteristics of patients, and the probability to maintain 
the TFR, the analysis was carried out first on all of the 142 
cases and then in the patients who discontinued the treatment 
(n = 111), grouped into two pairs of classes according to the 
RT‐qPCR and dPCR results at Time point 0: the MR4.0 vs 
MR4.5‐5.0 class, and ≥0.468 vs <0.468 BCR‐ABL1 copies/µL 
group (Tables 1 and 2).
The clinical and hematological characteristics of the pa-
tients grouped according to DMR classes (M4.0 vs MR4.5‐5.0) 
were superimposable, while the patients with dPCR <0.468 
had a longer DMR duration (P = 0.0250) and more fre-
quently belonged to MR4.5‐5.0 (P = 0.0442) classes compared 
to patients with higher dPCR values (Table 1).
Overall, 111/142 (78%) patients discontinued the TKI 
treatment after a median time of 97 months of TKI therapy 
F I G U R E  1  Levels of BCR‐ABL1 transcript measured by dPCR (y‐axis) according to different MR classes calculated by RT‐qPCR (x‐axis). 
RT‐qPCR BCR‐ABL1 results were grouped into MR4.0, MR4.5, and MR5.0 class (“X axis”). When the same samples were analyzed by dPCR, 
different levels of BCR‐ABL1 copies were measured (“Y axis”). The difference was statistically significant between the MR4.0 class and the MR4.5 
(P = 0.01) or the MR5.0 class (P = 0.003), but not between the MR4.5 and the MR5.0 classes (P = 0.2). The statistic test used was t test. In box and 
whiskers plot, center line represents the median values; the boxes’ limits represent the lower and the higher quartile; whiskers define the extreme 
values; and points represent the single analysis values
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(range 33‐194). MRD levels assessed by RT‐qPCR at the 
time of treatment discontinuation identified 45/111 (41%) 
patients with MR4.0 (23/45—51%—presented BCR‐ABL1 
transcript undetectable) and 66/111 (59%) with MR4.5‐5.0 
(45/66—68%—presented BCR‐ABL1 transcript undetect-
able). These patient groups, MR4.0 vs MR4.5‐5.0, did not show 
any significant statistical difference in clinical and hemato-
logical characteristics (Table 2).
By dPCR, 25/111 (23%) had ≥0.468 and 86/111 (77%) 
had <0.468. No significant statistical difference was ob-
served in clinical and hematological characteristics, except 
for a longer overall DMR duration in patients with dPCR 
<0.468 (76 vs 54 months. P = 0.0250) (Table 2).
At last follow‐up, 24/111 (22%) patients lost the MR3.0 
(10/24) or the MR4.0 (14/24) (Table 2). The median time 
of MR loss was 3 months from TKI discontinuation (range 
1‐19), with an incidence rate of 10.4 pt/year. Overall, the 
TFR was 83% at 6 months, 80% at 12 months, and 77% at 
24 months (Figure 3). According to RT‐qPCR at the time of 
TKI discontinuation, 9/45 were in MR4.0 (20%) and 15/66 
(23%) were in MR4.5‐5.0 (P = 0.8100); according to dPCR, 
12/25 (48%) and 12/86 (14%) had BCR‐ABL1 values ≥0.468 
and <0.468, respectively (P = 0.0003) (Table 2).
By survival analysis, no statistical significant differences 
according to different MR classes were found (Figure 4; 
P = 0.6510). An additional Kaplan‐Meier analysis was carried 
out on detectable MR4.0 vs total MR4.5‐5.0 (Supplementary 
File 3A), on MR4.0‐4.5 detectable and total MR5.0 (Figure 
S2B), and on MR4.0 detectable with MR4.5 detectable and 
F I G U R E  2  Molecular residual disease (MRD) over time as measured by RT‐qPCR and dPCR. (A) MRD monitoring by RT‐qPCR in patients 
with MR4.0 at Time Point 0. (B) MRD monitoring by RT‐qPCR in patients with MR4.5‐5.0 at Time Point 0. (C) MRD monitoring by dPCR in 
patients with value of BCR‐ABL1 copies/µL ≥0.468 at Time Point 0. (D) MRD monitoring by dPCR in patients with value of BCR‐ABL1 copies/µL 
<0.468 at Time Point 0
F I G U R E  3  Treatment‐free remission (TFR) curve of 111 
patients in deep molecular response (DMR) who discontinued TKI. 
The probability of maintaining TFR was 83%, 80%, and 77% at 6, 
12, and 24 months, respectively. The plot has been performed by the 
Kaplan‐Meier method
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MR5.0 at all (Figure S2C). In any cases, the consideration of 
the detectability of the transcript was not statistically signifi-
cant. On the contrary, a dPCR value below 0.468 BCR‐ABL1 
copies/µL at the time of discontinuation highly stratified pa-
tients with lower probability to lose MR Indeed, the TFR at 
1 and 2 years was 85% and 83% patients presenting dPCR 
values below the defined cutoff compared to 59% and 52% of 
patients with higher dPCR values at the time of discontinua-
tion, respectively (P = 0.0017) (Figure 5).
The univariate and multivariate analyses confirmed the pre-
dictive value of dPCR. In particular, DMR duration > 5 years 
(HR 0.2855, CI 95% 0.0931‐0.8760, P = 0.0284) and dPCR 
(HR 0.2936, CI 95% 0.1302‐0.6618, P = 0.0031) resulted sig-
nificantly predictable of TFR maintenance in univariate analysis. 
By multivariate analysis, only dPCR retained its significant value 
(HR 0.2124, CI 95% 0.0637‐0.7082, P = 0.0117 (Figure 6).
In 13 cases, a comparative monitoring of DMR by RT‐qPCR/
dPCR was possible for at least 24 months before TKIs discon-
tinuation. In these cases, 10 out of 13 (77%) had stable <0.468 
BCR‐ABL1 copies/µL by dPCR and 2/10 (20%) lost MR. On 
the other hand, 3/13 (23%) presented stable ≥0.468 BCR‐ABL1 
copies/µL by dPCR and 2/3 (67%) lost MR (P = 0.1245).
4 |  DISCUSSION
This study, based on a multicentric cohort of CML patients 
with durable DMR (≥2 years), shows that the dPCR appears 
to be more accurate and sensitive than conventional RT‐
qPCR for detecting and monitoring the BCR‐ABL1 molecu-
lar levels. Moreover, dPCR is potentially able to improve the 
recognition of DMR and the selection of the candidates to 
TKI treatment discontinuation.
The study reports on a longlasting comparative RT‐qPCR/
dPCR monitoring of BCR‐ABL1 transcript levels in 142 
CML patients having a median duration of TKI treatment 
and DMR of 8.3 years and 5.9 years, respectively. These 
long periods could explain why a very high TFR rate (80% 
at 1 year) was observed in our cohort of patients, in compar-
ison to an expected rate of 50%‐60%, usually reported in the 
literature.6,7 Notably, the TKI exposure and DMR duration 
was 4.8 and 3 years in STIM trial, 6 and 3.3 years in IFN‐
IM cohort of Twister trial, and 6.3 and 2.4 in STOP 2G‐TKI 
study, respectively. Durable DMR, more than the duration of 
TKI treatment, is considered the most important modifiable 
prognostic factor playing a key role for TKI discontinuation 
success, but at present, there is no general agreement on the 
duration either of the TKIs therapy or of DMR. 11
Indeed, ESMO recommends at least 5 years of TKI ther-
apy combined with ≥2 years of DMR before TKI discontinu-
ation,13 while the French CML Study Group requires at least 
2 years of MR4.5 before discontinuation in order to reach the 
TFR. Moreover, a great uncertainty still remains for the level 
of MR.12
Considering the pivotal clinical trials concerning TKI dis-
continuation, in EURO‐SKI study, a threshold of 3.1 years of 
F I G U R E  4  Treatment‐free remission (TFR) curves according to 
MR class measured by RT‐qPCR at the time of discontinuation. The 
red curve represents patients discontinued with MR4.0, and the black 
curve patients with MR4.5‐5.0. The probability of maintaining TFR for 
patients discontinued with MR4.0 was 80% at both 1 and 2 years. The 
probability of maintaining TFR for patients discontinued with MR4.5‐5.0 
was 79% and 74% at 1 and 2 years, respectively. Kaplan‐Meier analysis 
was used for the evaluation of TFR. Comparison of subgroups was 
carried out by the log‐rank test
F I G U R E  5  Treatment‐free remission (TFR) curves according 
to dPCR values. The red curve represents patients discontinued with 
a dPCR value lower than 0.468 and the black curve patients with a 
dPCR value higher than 0.468. The probability of maintaining TFR for 
patients discontinued with dPCR <0.468 was 85% and 83% at 1 and 
2 years, respectively. The probability of maintaining TFR for patients 
discontinued with dPCR ≥ 0.468 was 59% and 52% at 1 and 2 years, 
respectively. A Kaplan‐Meier analysis was used for the evaluation of 
TFR. Comparison of subgroups was carried out by a log‐rank test
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MR4.0 was identified as dissecting the patients with the lowest 
probabilities to lose the TFR. 30 In the JALSG‐STIM213 trial, 
patients in MR5.0 undetectable before IM or nilotinib discon-
tinuation had significantly higher probabilities to maintain 
the TFR than those in MR4.5. 31,32 In the STIM study, the 
following duration of the treatment was considered: at least 
3 years of IM was required, with at least 2 years of MR4.5 
undetectable levels of BCR‐ABL1 quantified following the IS 
system. 7
It clearly appears that the sensitivity and the detectabil-
ity of BCR‐ABL1 transcript are additional elements that may 
play an important role. In fact, because of its low sensitivity, 
RT‐qPCR could not discriminate the depth of response in pa-
tients with undetectable BCR‐ABL1 transcript and a patient 
with undetectable MR4.0 could belong to MR5.0.
In our experience, the majority of the samples classified 
as DMR had an undetectable level of transcript, confirming 
the low RT‐qPCR capability to detect low levels of MRD 
while the dPCR appeared to overcome this important bias 
thanks to its high sensitivity and accuracy, allowing a bet-
ter selection of patients eligible for TKI discontinuation. Our 
data, according to Takahashi and colleagues,31 encourage 
TFR studies using dPCR, offering better quantitative accu-
racy than RT‐qPCR IS for DMR.
Looking at our RT‐qPCR and dPCR comparative analysis 
and monitoring, dPCR allowed to highlight a high hetero-
geneity of MRD levels in patients belonging the same class 
of MR at the Time point 0. Indeed, measuring the absolute 
number of BCR‐ABL1 copies/µL by dPCR, it was evident 
that both the patients with MR4.0 and those with MR4.5‐5.0 
had different levels of MRD (Figure 1). Importantly, abso-
lute numbers of BCR‐ABL1 copies/µL could be detected and 
measured also in MR4.0, MR4.5, or MR5.0 patients with unde-
tectable BCR‐ABL1 transcripts by RT‐qPCR.
Furthermore, due to a sort of “normalizing” effect of RT‐
qPCR, the courses of the patients monitored by RT‐qPCR did 
not allow the identification of patients with “stable” DMR 
from the patients with the “unstable” DMR, neither in the 
group of MR4.0 responses nor in the group of MR4.5‐5.0 re-
sponses, independently from a detectable or undetectable 
BCR‐ABL1 transcript.
Observing MRD courses by dPCR in the group of pa-
tients with ≥ or <0.468 BCR‐ABL1 copies/µL, it was possi-
ble to appreciate a specific trend for each patient. Moreover, 
patients presenting MRD levels <0.468 BCR‐ABL1 copies/
µL at Time point 0, apparently showed lower levels of tran-
script along all the follow‐up than patients with MRD levels 
≥0.468 BCR‐ABL1 copies/µL, even if we did not find any 
statistical difference between median levels of ≥ and <0.468 
BCR‐ABL1 copies/µL groups. Lacking of a statistically sig-
nificant difference could be due to the narrow range of values 
measured by dPCR and to the needing of a dPCR power test, 
focused on this end point and carried out on a larger cohort 
of CML patients.
These data suggest that the dPCR may be able to identify a 
set of optimal and stable molecular responders based on the lev-
els and the stability of MRD (<0.468 BCR‐ABL1 copies/µL).
One hundred and eleven patients discontinued the TKI 
treatment and 24 (22%) of them lost the MR3.0 or the MR4.0 
according to the criteria reported by Etienne et al.6
F I G U R E  6  Univariate and multivariate analyses for the prediction of treatment‐free remission (TFR). (A) Univariate Cox regression 
analysis. Variables included were age at diagnosis, sex, previous therapy with IFN, time to MMR and DMR, Sokal class, type of transcript, 
time to discontinuation, use of frontline second‐generation TKIs, MR classes considering detectable and undetectable transcript, and dPCR. 
DMR duration > 5 years (HR 0.2855, CI 95% 0.0931‐0.8760, P = 0.0284) and dPCR (HR 0.2936, CI 95% 0.1302‐0.6618, P = 0.0031) 
resulted significantly predictable of TFR maintenance. (B) Multivariate analysis—only dPCR retained its significant value (HR 0.2124, CI 95% 
0.0637‐0.7082, P = 0.0117)
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In our cohort of patients, the TFR rate was higher than 
the one currently reported in the IM and second‐generation 
TKI discontinuation studies31,32 but, as expected, the loss of 
MR occurred in 24/111 (22%) cases early after TKIs discon-
tinuation (3 months). This highly positive selection could 
be explained, as above reported, by the prolonged treatment 
and the DMR duration.30,31 Furthermore, the major part of 
the patients (75%) who underwent TKIs discontinuation was 
characterized by the presence of the transcript b3a2. This 
transcript has been recently associated with a better response 
to the TKIs treatment, resulting in higher sustained DMR 
rate,39 and a longer TFR.40It has to be underlined that con-
sidering our entire cohort, patients with <0.468 dPCR values 
of MRD had also a significantly longer duration of DMR and 
this seemed to significantly translate in a lower rate of loss of 
MR, either MR3.0 or MR4.0.
By the way, the rate of MR3.0 or MR4.0 loss in the cases with 
<0.468 BCR‐ABL1 copies/µL by dPCR resulted significantly 
lower (14%) than one of the cases with ≥0.468 BCR‐ABL1 
copies/µL (48%). Indeed, the probability to predict the TFR 
was 86% for the cases with <0.468 BCR‐ABL1 copies/µL and 
52% for the cases with ≥0.468 BCR‐ABL1 copies/µL, and this 
difference was statistically significant (P=0.0003) (Table 2).
Looking at the clinical and hematological characteristics 
of these two groups of patients, they resulted comparable, ex-
cept for the longer duration of DMR (P = 0.025).
Interestingly, these data first showed a potential correla-
tion between the duration and stability of DMR and a measur-
able reduction of molecular levels of BCR‐ABL1 transcript. 
In our opinion, they suggest the value <0.468 BCR‐ABL1 
copies/µL of transcript by dPCR would reflect the threshold 
of BCR‐ABL1 transcript suitable for a higher probability of 
treatment discontinuation success. In fact, in our study, the 
dPCR resulted the only parameter associated with TFR by 
multivariate analysis (Figure 6), while no statistically signif-
icant difference (P = 0.6510) was observed between the rate 
of MR loss of patients with MR4.0 (detectable or undetect-
able) vs MR4.5‐5.0 (detectable or undetectable) (Figure 4).
There is general agreement on considering RT‐qPCR not 
sufficiently adequate to measure low levels of BCR‐ABL1 
transcripts and this has to be considered particularly relevant 
in the era of the more potent second‐generation TKIs. 25,38 
However, while everybody knows the limits of RT‐qPCR, 
newly available technologies have not been yet introduced in 
the quantification of the MRD, particularly in the setting of 
deep responders CML patients, possible candidates to TKIs 
discontinuation.
In order to routinely apply dPCR for BCR‐ABL1 detection 
and quantification for a personalized management of CML 
patients, other efforts have to be performed in the standard-
ization of the procedures and in the alignment of the results 
generated by the different dPCR platforms.22,24,41
No firm conclusion can be drawn and, certainly, the 
higher accuracy, sensitivity, and predictive value of dPCR 
have to be prospectively confirmed on a larger cohort of 
cases. However, this study practically tested the potential of 
dPCR and highlighted that this technique is able to detect 
measurable quantities of BCR‐ABL1 transcripts in the cases 
with undetectable DMR by RT‐qPCR; that patients belong-
ing to the same MR class do not have the same quantities 
of BCR‐ABL1 transcript when measured by dPCR; and that 
dPCR may improve the recognition of “stable” DMR, hence 
contributing to a better selection of candidates to TKIs 
discontinuation.
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